Remove Bioequivalency Remove In-Vivo Remove Regulation
article thumbnail

In the News: October Regulatory and Development Updates

Camargo

Labeling regulations prohibit reminder ads for products with boxed warnings, which the FDA requires when a drug product has very serious risks. Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program.

article thumbnail

Innovative Approaches to Generic Drug Development: Case Studies

Drug Patent Watch

The Thyroid Association’s Concerns The American Thyroid Association (ATA) had raised concerns about the FDA’s methods for determining bioequivalence between levothyroxine products[2]. These allow manufacturers to skip certain in vivo studies, saving time and resources[3].